The fight to curtail “pay-for-delay” or “reverse payment” settlements between pharmaceutical patent holders and generic drug makers received a shot in the arm on Monday, as the Supreme Court held this week that these agreements are not immune from antitrust scrutiny.[1] The decision, however, was not a complete victory for either regulators or private plaintiffs. … Continue reading